Phase II Study of a Bi-Weekly Chemotherapy Regimen of Combined Liposomal Paclitaxel and Nedaplatin for the Treatment of Advanced Squamous Cell Lung Cancer
The platinum-based, two-drug, 3-week regimen is currently the main first-line chemotherapy program for the treatment of advanced squamous cell lung cancer. The aim of this phase II clinical study was to evaluate the efficacy and adverse events of the bi-weekly program of liposomal paclitaxel combine...
Main Authors: | Wei-Ze Lv, Zhong Lin, Si-Yang Wang, Bao-Jun Lv, Zhi-Hui Wang, Mei Xiao, Xiao-Lu Xu, Pei-Jian Peng |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-04-01
|
Series: | Translational Oncology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523318306168 |
Similar Items
-
Evaluation of the tumor load and adverse reactions of nedaplatin combined with paclitaxel liposome and with paclitaxel treatment of advanced esophageal cancer
by: Jun-Ying Liang1, et al.
Published: (2017-04-01) -
Multi-institutional prospective study of nedaplatin plus S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens
by: Pei-Jian Peng, et al.
Published: (2017-02-01) -
Nedaplatin: a cisplatin derivative in cancer chemotherapy
by: Shimada M, et al.
Published: (2013-05-01) -
Effect of paclitaxel liposome combined with nedaplatin on serum HE4, CA125, CA19-9, AFP, CEA and T lymphocyte subsets in patients with advanced ovarian cancer
by: Su-Yu Zhu, et al.
Published: (2016-08-01) -
Efficacy and safety of pemetrexed and nedaplatin followed by pemetrexed maintenance therapy in advanced lung adenocarcinoma
by: Lin Z, et al.
Published: (2017-11-01)